Laidlaw Capital Markets is pleased to announce today’s pricing of a $21,750,000 Follow-On Offering for EyePoint Pharmaceuticals (EYPT). Laidlaw proudly served as Co-Manager alongside Guggenheim, who was Sole Book-Runner on the transaction.

See full Press Release on Eyepoint Website